Low Bone Mass
5
0
0
5
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 17/100
0.0%
0 terminated out of 5 trials
100.0%
+13.5% vs benchmark
40%
2 trials in Phase 3/4
60%
3 of 5 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 5 completed trials
Clinical Trials (5)
Resveratrol for the Prevention of Bone Loss in Postmenopausal Women
DHEA Augmentation of Musculoskeletal Adaptations to Exercise in Older Women
Study to Compare the Efficacy and Safety of DenosumAb Versus Placebo in Males With Osteoporosis
A High-resolution Peripheral Quantitative Computed Tomography Study in Postmenopausal Women Previously Treated With Denosumab
A Transiliac Crest Bone Histology and Histomorphometry Study in Postmenopausal Women With Low Bone Mass or Osteoporosis Previously Treated With Denosumab